CA-VELODYNE/SEOUL-ROBO
27.2.2020 14:02:13 CET | Business Wire | Press release
Velodyne Lidar, Inc. (Booth #6091), in collaboration with Seoul Robotics , will demonstrate how its smart, powerful lidar solutions advance automation and safety in manufacturing and supply chain solutions at MODEX 2020 in Atlanta, March 9-12. Velodyne will highlight lidar sensors that can be used in robotics, automated guided vehicles (AGV), forklifts and security applications. Velodyne lidar solutions can improve industrial automation, materials handling, yard management and distribution center operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005194/en/
At its MODEX booth, Velodyne will showcase the Puck 32MR™, a lidar sensor which produces a data-rich image with the ability to detect low reflectivity objects at a range of 120 meters. The sensor is optimized for outstanding indoor/outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, the Puck 32MR accurately detects crosswalks, curbs and obstacles in warehouse aisles for safe and efficient navigation in roadway, commercial and industrial settings.
Velodyne will also highlight the Velarray™, a powerful sensor solution to greatly improve automated safety. Its small, embeddable form factor enables the sensor to be seamlessly integrated into a variety of industrial and robotics equipment. The Velarray produces a robust directional image, day or night.
“As the demands for supply chain efficiency and safety increase and evolve, lidar technology is helping companies vastly improve manufacturing and logistics performance,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Supply chain systems need to continue to become smarter and safer, more efficient and further automated. To address these requirements, companies are turning to lidar to play a key role in enabling the next generation of manufacturing and supply chain solutions.”
At Velodyne’s MODEX booth, Seoul Robotics will demonstrate the benefits and applications of Level 5 Control Tower solution, powered by its proprietary AI engine, SENSR™, which is optimized and available commercially to process Velodyne’s rich and reliable 3D data. Seoul Robotics uses artificial intelligence (AI) for detection, counting, classification and tracking of objects in real time. It can accurately track the location, coordinates, speed and direction of objects and predict their path, such as vehicles and people at a distribution center or manufacturing and logistics operation.
“As vehicles and material handling equipment are increasingly automated in logistics yards and distribution centers, industry must develop and deploy in parallel a robust and safe operating environment. This will resolve well-known challenges with trucks and equipment, such as blind spots and occlusion, in order to successfully realize the promised efficiency and economy,” said David Han, Seoul Robotics’ Managing Director of North America & Global Automotive. “Level 5 Control Tower equipped with Velodyne lidar enables exactly that – a robust and cost-effective infrastructure-based perception solution that monitors and guides the movement of automated and conventional vehicles within the entire yard – efficiently and safely.”
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Seoul Robotics
Seoul Robotics is a 3D Perception AI company that specializes in Lidar perception solutions, powered by its proprietary and versatile SENSR™ perception platform suite. Based in Seoul, South Korea with U.S. branch office in Ann Arbor, Michigan, Seoul Robotics is developing customers and projects in the ADAS/AV, Security, Smart Factory and Logistics, and Robotics markets worldwide. Seoul Robotics works collaboratively with partners across the value chain – including Lidar manufacturers, global automotive and industrial OEM’s and Tier 1 & 2 suppliers, engineering companies, and government customers – to advance perception solutions that make robots intelligent. Visit www.seoulrobotics.org for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005194/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
